GlassScriptPhysician profile
Michele B Weiberg
NPI 1356550057
$1,012.52
in general payments reported to CMS, 2019-2025
23 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $39.99 · 2022: $15.08 · 2024: $200 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.88 | 2024 | |
| Pfizer INC. | $103.59 | 2024-2025 | |
| Viiv Healthcare Company | $97.76 | 2025 | Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $77.87 | 2019-2025 | Pifeltro, Capvaxive |
| Baxter Healthcare | $70.33 | 2025 | Hillrom - Monarch Airway Clearance System |
| Gilead Sciences, INC. | $65.71 | 2025 | Biktarvy |
| Takeda Pharmaceuticals U.S.A., INC. | $50.10 | 2025 | Glassia |
| Cumberland Pharmaceuticals, INC. | $46.92 | 2025 | Vibativ |
| Aimmune Therapeutics, INC. | $40.73 | 2025 | Vowst |
| Astellas Pharma US INC | $39.99 | 2021 | |
| Grifols USA, LLC | $39.03 | 2025 | Prolastin-C Liquid |
| Mayne Pharma Commercial LLC | $31.90 | 2019 | |
| Melinta Therapeutics, LLC | $31.44 | 2019 | |
| Mylan Specialty L.P. | $23.44 | 2019 | |
| Pulmonx Corporation | $21.54 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $21.42 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $20.00 | 2025 | |
| Ferring Pharmaceuticals INC. | $19.84 | 2025 | Rebyota |
| Janssen Biotech, INC. | $19.61 | 2019 | |
| Philips North America LLC | $19.32 | 2025 | Vest Therapy Und |
| Astrazeneca Pharmaceuticals LP | $16.53 | 2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $16.49 | 2025 | Acthar |
| Abbvie INC. | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Weiberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.